secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outset Medical, Inc. (OM)
CIK:        0001484612
Form:       8-K
Filed at:   2026-01-27T23:59:59+00:00
Accession:  0001193125-26-023428
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outset Medical receives FDA 510(k) clearance for next-generation Tablo dialysis system; Q2 2026 launch
--------------------------------------------------------------------------------

- FDA 510(k) clearance granted for next-gen Tablo platform on January 27, 2026.
- Tablo is first dialysis system to meet FDA's most rigorous cybersecurity guidance (June 2025).
- Hardware, operating system, and software enhancements improve reliability and user experience.
- Shipping to customers expected to begin in Q2 2026; current users eligible to upgrade.
- CEO Leslie Trigg highlights milestone as reflecting commitment to innovation and patient safety.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484612/000119312526023428/0001193125-26-023428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484612/000119312526023428/om-20260127.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-023428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer